Zanaflu will be the brand name for ANX-211, also known as chitosan gel, an intranasal/topical antiviral that has demonstrated efficacy against viruses responsible for the common cold, influenza, and other respiratory tract viral infections. U.S. rights to the product were recently acquired from Adventrx Pharmaceuticals by TRx Pharma. The company plans to launch Zanaflu for the 2007 cold and influenza season.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
